Editor - Ramasamy Paulmurugan | Stanford University School of Me | 7371

OMICS Journal of Radiology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Ramasamy Paulmurugan

Ramasamy Paulmurugan
Ramasamy Paulmurugan
Stanford University School of Medicine
Tel. 650-725-6097
Fax 650-721-6921
Stanford University School of Medicine


 Dr. Ramasamy Paulmurugan is Assistant Professor in Radiology at Stanford University School of Medicine. He received his Masters in Biomedical Genetics and Ph.D. in Molecular Virology from the University of Madras, India. After serving as scientist for four years, he joined the School of Medicine at University of California, Los Angeles as a visiting scientist. In 2003 he moved to Stanford as a Senior Research Scientist. Since 2009 he has been working as Assistant Professor at the Department of Radiology in Stanford University under the Molecular Imaging Program (MIPS). He is a pioneer in developing split-reporter protein complementation systems for different reporter genes (luciferases, fluorescent proteins and thymidine kinase) and has been using the system for imaging cellular protein-protein interactions in living animals. Currently his lab (Cellular Pathway Imaging Laboratory (CPIL)) is working on the application of different imaging strategies to evaluate the therapeutic role of ERbeta, another important estrogen receptor, which has been recently identified as one of the major player in Estrogen biology.

Research Interest

Dr. Ramasamy Paulmurugan Imaging cellular signal transduction networks in living animals by multimodality molecular imaging techniques (Optical, PET and CT). Developing novel gene therapy for treating different cancers. MicroRNA therapy for triple negative breast cancer.